Orsini Specialty Pharmacy announced today that it is now dispensing tiopronin, the first available generic version, in the US, of THIOLA® (tiopronin).
|
ELK GROVE VILLAGE, Ill., July 22, 2021 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that it is now dispensing tiopronin, the first available generic version, in the US, of THIOLA® (tiopronin). Tiopronin is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients nine years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. For more information about tiopronin, please see the Full Prescribing Information.
Cystinuria is a rare, inherited disease characterized by the build-up of the amino acid cystine, a building block of most proteins, in the kidneys and bladder. As the kidneys filter blood to create urine, cystine is usually absorbed back into the bloodstream. People with cystinuria cannot properly reabsorb cystine into their bloodstream, so the amino acid accumulates in their urine, resulting in cystine crystals and/or stones in the kidneys or bladder. Cystinuria affects approximately one in 10,000 people of all genders, races, ethnicities, and ages in the US. "The entire team at Orsini is devoted to exceptional patient care to meet the individual needs of patients and their families," said Mike Fieri, Orsini Founder and Chief Executive Officer. "High touch care coordination and collaboration drive our unique pharmacy care model, and we are honored to help provide access to tiopronin to patients with severe homozygous cystinuria." About Orsini Specialty Pharmacy THIOLA® is a registered trademark of Mission Pharmacal Company.
SOURCE Orsini Specialty Pharmacy |
View original content to download multimedia:
